Complement is an important pathway in innate immunity, inflammation, and many disease processes. However, despite its importance, there have been few validated mathematical models of complement activation. In this study, we developed an ensemble of experimentally validated reduced order complement models. We combined ordinary differential equations with logical rules to produce a compact yet predictive complement model. The model, which described the lectin and alternative pathways, was an order of magnitude smaller than comparable models in the literature. We estimated an ensemble of model parameters from in vitro dynamic measurements of the C3a and C5a complement proteins. Subsequently, we validated the model on unseen C3a and C5a measurements not used for model training. Despite its small size, the model was surprisingly predictive.
Introduction
and undergoes a conformational change, leading to an activated form with proteolytic ac-27 tivity. The activated complex cleaves soluble complement proteins C4 and C2 into C4a, 28 C4b, C2a and C2b, respectively. The C4a and C2b fragments bind to form the C4bC2a 29 protease, also known as the classical pathway C3 convertase (CP C3 convertase). The 30 lectin pathway is initiated through the binding of L-ficolin or Mannose Binding Lectin (MBL) 31 to carbohydrates on the surfaces of bacterial pathogens. These complexes, in combina-32 tion mannose-associated serine proteases 1 and 2 (MASP-1/2), also cleave C4 and C2, 33 leading to additional CP C3 convertase. Thus, the classical and lectin pathways, initiated 34 by different cues on foreign surfaces, converge at the CP C3 convertase. However, the 35 alternate pathway works differently. It is activated by a 'tickover' mechanism in which com-36 plement protein C3 is spontaneously hydrolyzed to form an activated intermediate C3w; 37 C3w recruits factor B and factor D, leading to the formation of C3wBb. C3wBb cleaves C3 38 into C3a and C3b, where the C3b fragment further recruits additional factor B and factor D 39 to form C3bBb, the alternate C3 convertase (AP C3 convertase) (9). The role of classical 40 and alternate C3 convertases is varied. First, AP C3 convertases mediate signal amplifi-41 cation. AP C3 convertases cleave C3 into C3a and C3b; the C3b fragment is then free to 42 form additional alternate C3 convertases, thereby forming a positive feedback loop. Next, 43 AP/CP C3 convertases link complement initiation with the terminal phase of the cascade 44 through the formation of C5 convertases. Both classical and alternate C3 convertases 45 can recruit C3b subunits to form the classical pathway C5 convertase (C4bC2aC3b, CP 46 C5 convertase), and the alternate pathway C5 convertase (C3bBbC3b, AP C5 convertase), respectively. Both C5 convertases cleave C5 into the C5a and C5b fragments. The 48 C5b fragment, along with the complement proteins C6, C7, C8 and multiple C9s, form 49 the membrane attack complex. On the other hand, both C3a and C5a are important in-50 flammatory signals involved in several responses (7, 8) . Thus, the complement cascade 51 attacks invading pathogens, while acting as a beacon for adaptive immunity. 52 The complement cascade is regulated by plasma and host cell proteins which balance 53 host safety with effectiveness. The initiation of the classical pathway via complement 54 protein C1 is controlled by the C1 Inhibitor (C1-Inh); C1-Inh irreversibly binds to and de- 55 activates the active subunits of C1, preventing chronic complement activation (10). Regu-56 lation of upstream processes in the lectin and alternate pathways also occurs through the 57 interaction of the C4 binding protein (C4BP) with C4b, and factor H with C3b (11). Interest-58 ingly, both factor H and C4BP are capable of binding their respective targets while in con- 59 vertase complexes as well. At the host cell surface, membrane cofactor protein (MCP or 60 CD46) can interact with C4b and C3b, which protects the host cell from complement self-61 activation (12). Delay accelerating factor (DAF or CD55) also recognizes and dissociates 62 both C3 and C5 convertases on host cell surfaces (13). More generally the well known 63 inflammation regulator Carboxypeptidase-N has broad activity against the complement 64 proteins C3a, C4a, and C5a, rendering them inactive by cleavage of carboxyl-terminal 65 arginine and lysine residues (14). Although Carboxypeptidase-N does not directly influ-66 ence complement activation, it silences the important inflammatory signals produced by 67 complement. Lastly, assembly of the MAC complex itself can be inhibited by vitronectin 68 and clusterin in the plasma, and CD59 at the host surface (15, 16) . Thus, there are many 69 points of control which influence complement across the three activation pathways. 70 Developing quantitative mathematical models of complement will be crucial to fully un- 71 derstanding its role in the body. Traditionally, complement models have been formulated 72 as systems of linear or non-linear ordinary differential equations (ODEs 
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In this study, we developed an ensemble of experimentally validated reduced order com-95 plement models using multiobjective optimization. The modeling approach combined or-96 dinary differential equations with logical rules to produce a complement model with a lim-97 ited number of equations and parameters. The reduced order model, which described the 98 lectin and alternative pathways, consisted of 18 differential equations with 28 parameters. 99 Thus, the model was an order of magnitude smaller and included more pathways than 100 comparable models in the literature. fragments. In this initial study, we simplified the model by assuming both factor B and 127 factor D were in excess. However, we did explicitly account for two control proteins, fac-128 tor H and C4BP. Lastly, we did not consider MAC formation, instead we stopped at C5a The complement model ensemble captured the behavior of both the alternate and lectin 151 pathways ( Fig. 2 ). For the alternate pathway, we used C3a and C5a measurements in the 152 absence of zymosan ( Fig. 2A and B ). On the other hand, lectin pathway parameters were 153 estimated from C3a and C5a measurements in the presence of 1mg/ml zymosan ( ics were too fast with the exception of the low dose case. We believe the C3a time scale 171 was related to our choice of training data, how we modeled the tickover mechanism, and 172 factor B and D limitation. We trained the model using either no or 1 mg/ml zymosan, but 173 predicted cases in a different initiator range; comparing training to prediction, the model 174 performance e.g., the shape of the C3a trajectory was biased towards either high or very 175 low initiator doses. Next, tickover was modeled as a first-order generation processes 176 where C3wBb formation and activity was lumped into the AP C3 convertase. Thus, we 177 skipped an important upstream step which could strongly influence AP C3 convertase 178 formation by slowing down the rate C3 cleavage into C3a and C3b. We also assumed 179 both factor B and factor D were not limiting, thereby artificially accelerating the rate of 180 AP C3 convertase formation. The C5a predictions followed a similar trend as C3a; we 181 captured the long-time C5a behavior but over predicted the time scale of C5 cleavage. 182 However, because the C5a time scale depends strongly upon C3 convertase formation, 183 we can likely correct the C5 issues by fixing the rate of C3 cleavage. Despite these short-184 comings, we qualitatively predicted unseen experimental measurements typically within 185 the 99% confidence of the ensemble, for three inducer levels. Next, we used global sensi- On the other hand, the C5a residual was controlled by the formation and activity of CP 202 C5 convertase, and tickover C3b formation in the presence of zymosan (Fig. 4B ). The 203 lectin initiation parameters were sensitive, but to a lesser extent than CP convertase ki-204 netic parameters and tickover C3b formation. Thus, sensitivity analysis suggested that 205 CP C3/C5 convertase formation and activity dominated in the presence of zymosan, but 206 tickover parameters and AP C5 convertase were more important without initiator. AP C3 207 convertase assembly was important, but its activity was not. Next, we compared the sen-208 sitivity results to current therapeutic approaches; pathways involving sensitive parameters 209 have been targeted for clinical intervention (Fig. 4C ). In particular, the sensitivity analysis 210 suggested AP/CP C5 convertase inhibitors, or interventions aimed at attenuating C3 or 211 C5 would most strongly influence complement performance. Thus, there was at least a 212 qualitative overlap between sensitivity and the potential of biochemical efficacy. However, 213 sensitivity coefficients are only a local measure of how small changes in parameters affect 214 model performance. To more closely simulate a clinical intervention e.g., administration 215 of an anti-complement inhibitor, we performed robustness analysis. 216 Robustness analysis suggested there was no single intervention that inhibited com-217 plement activation in the presence of both initiation pathways ( Fig. 5 ). Robustness co-218 efficients quantify the response of a protein to a macroscopic structural or operational 219 perturbation to a biochemical network. Here, we computed how the C3a and C5a trajec-220 tories responded to a decrease in the initial abundance of C3 and/or C5 with and without 221 lectin initiator. We simulated the addition of different doses of anti-complement inhibitor 222 cocktails by decreasing the initial concentration of C3, C5 or the combination of C3 and 223 C5 by 50%, 90% and 99%. This would be conceptually analogous to the administration 224 of a C3 inhibitor e.g., Compstatin alone or combination with Eculizumab (Fig. 4C ). The 225 response of the complement model to different knock-down magnitudes was non-linear; a 226 90% knock-down had an order of magnitude more impact than a 50% knock-down. As ex-227 pected, a C5 knockdown had no effect on C3a formation for either the alternate (Fig. 5A ) 228 or lectin pathways (Fig. 5B ). However, C3a and to a greater extent C5a abundance de- In this study, we developed an ensemble of experimentally validated reduced order com-242 plement models using multiobjective optimization. The modeling approach combined or-243 dinary differential equations with logical rules to produce a complement model with a lim-244 ited number of equations and parameters. The reduced order model, which described the 245 lectin and alternative pathways, consisted of 18 differential equations with 28 parameters. 246 Thus, the model was an order of magnitude smaller and included more pathways than where C3wBb catalyzes C3 cleavage at a slow rate compared to normal AP or CP C3 334 convertases. We also assumed both factor B and factor D were not limiting, thereby ar-335 tificially accelerating the rate of AP C3 convertase formation. This shortcoming could be 336 addressed by including balances around factor B and D, and including these species in 337 the appropriate kinetic rates. The C5a predictions also had an accelerated time scale. 338 However, because the C5a time scale depended strongly upon C3 convertase formation, 339 we can likely correct the C5 issues by fixing the rate of C3 cleavage. Lastly, we should 340 also consider including the C2-bypass pathway, which was not included in the model. 341 The C2-bypass mediates lectin pathway activation, without the involvement of MASP-1/2. 342 Thus, this pathway could be important for understanding the role of MASP-1/2 inhibitors 343 on complement activation.
344
Materials and Methods
Formulation and solution of the complement model equations. We used ordinary 346 differential equations (ODEs) to model the time evolution of complement proteins (x i ) in 347 the reduced order model:
where R denotes the number of reactions and M denotes the number of proteins in Rate processes were written as the product of a kinetic term (r j ) and a control term 359 (v j ) in the complement model. The kinetic term for the formation of C4a, C4b, C2a and 360 C2b, lectin pathway activation, and C3 and C5 convertase activity was given by:
where k max j denotes the maximum rate for reaction j, i denotes the abundance of the 362 enzyme catalyzing reaction j, η denotes a cooperativity parameter, and K js denotes the 363 saturation constant for species s in reaction j. We used mass action kinetics to model 364 protein-protein binding interactions within the network:
where k max j denotes the maximum rate for reaction j, σ sj denotes the stoichiometric coef-366 ficient for species s in reaction j, and s ∈ m j denotes the set of reactants for reaction j. 367 We assumed all binding interactions were irreversible. 
where Z i denotes the abundance of factor i, k ij denotes a gain parameter, and η ij denotes 376 a cooperativity parameter. In this study, we used I j ∈ {min, max} (39 Robustness coefficients quantify the response of a marker to a structural or operational 423 perturbation to the network architecture. Robustness coefficients were calculated as 424 shown previously (48). Log-transformed robustness coefficients denoted byα (i, j, t o , t f ) 425 are defined as:
Here t o and t f denote the initial and final simulation time, while i and j denote the indices 427 for the marker and the perturbation, respectively. A value ofα (i, j, t o , t f ) > 0, indicates 428 increased marker abundance, whileα (i, j, t o , t f ) < 0 indicates decreased marker abun-429 dance following perturbation j. Ifα (i, j, t o , t f ) ∼ 0, perturbation j did not influence the 430 abundance of marker i. In this study, we perturbed the initial condition of C3 or C5 or 431 a combination of C3 and C5 by 50%, 90% and 99% and measured the area under the 432 curve (AUC) of C3a or C5a with and without lectin initiator. We computed the robustness 433 coefficients for a subset of the parameter ensemble. Fig. 2 : Reduced order complement model training. An ensemble of model parameters were estimated using multiobjective optimization from C3a and C5a measurements with and without zymosan (20). The model was trained using C3a and C5a data generated from the alternative pathway (A-B) and lectin pathway initiated with 1 mg/ml zymosan (C-D). The solid black lines show the simulated mean value of C3a or C5a for the ensemble, while the dark shaded region denotes the 99% confidence interval of mean. The light shaded region denotes the 99% confidence interval of the simulated C3a and C5a concentration. All initial conditions were assumed to be at their physiological serum levels unless otherwise noted. Fig. 3 : Reduced order complement model predictions. Simulations of C3a and C5a generated in the lectin pathway using 0.1 mg/ml, 0.01 mg/ml, and 0.001 mg/ml zymosan were compared with the corresponding experimental measurements. The solid black lines show the simulated mean value of C3a or C5a for the ensemble, while the dark shaded region denotes the 99% confidence interval of mean. The light shaded region denotes the 99% confidence interval of the simulated C3a and C5a concentration. All initial conditions were assumed to be at their physiological serum levels unless otherwise noted. 5 : Robustness analysis of the complement model. Robustness coefficients were calculated for a 50%, 90% and 99% reduction in C3, C5, or C3 and C5 initial conditions. A: Mean robustness index for C3a and C5a generated from the alternate pathway (w/o zymosan). B: Mean robustness index for C3a and C5a generated from the lectin and alternate pathway (1 mg/ml zymosan). The color describes the degree of reduction of C3a or C5a following the network perturbation. Robustness coefficients were calculated using all parameter sets with Pareto rank less than five (N = 65).
Sensitivity
